Narita K, Amiya E. Is branched-chain amino acid nutritional supplementation beneficial or detrimental in heart failure? World J Cardiol 2021; 13(6): 163-169 [PMID: 34194634 DOI: 10.4330/wjc.v13.i6.163]
Corresponding Author of This Article
Eisuke Amiya, MD, PhD, Academic Research, Department of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Tokyo 113-8655, Japan. amiyae-tky@umin.ac.jp
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Jun 26, 2021; 13(6): 163-169 Published online Jun 26, 2021. doi: 10.4330/wjc.v13.i6.163
Is branched-chain amino acid nutritional supplementation beneficial or detrimental in heart failure?
Koichi Narita, Eisuke Amiya
Koichi Narita, Eisuke Amiya, Department of Cardiovascular Medicine, The University of Tokyo, Tokyo 113-8655, Japan
Author contributions: Amiya E contributed to the conception and design of the research; Narita K contributed to the acquisition and analysis of the data; Narita K and Amiya E contributed to the interpretation of the data; and Narita K and Amiya E drafted the manuscript; all authors critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.
Conflict-of-interest statement: Amiya E belongs to the Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, which is endowed by Actelion Pharmaceuticals Japan Ltd., Otsuka Pharmaceutical, NIPRO CORPORATION, Terumo Corp., Senko Medical Instrument Mfg., Century Medical Inc., Kinetic Concepts Inc., and St. Jude Medical. The other author has no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Eisuke Amiya, MD, PhD, Academic Research, Department of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Tokyo 113-8655, Japan. amiyae-tky@umin.ac.jp
Received: February 5, 2021 Peer-review started: February 5, 2021 First decision: February 28, 2021 Revised: March 12, 2021 Accepted: May 22, 2021 Article in press: May 22, 2021 Published online: June 26, 2021 Processing time: 136 Days and 12 Hours
Abstract
Sarcopenia or cachexia is often complicated in heart failure. Nutritional support, particularly branched-chain amino acid (BCAA) supplementation, is a candidate treatment for improving sarcopenia or cachexia in elderly patients. However, the efficacy of BCAA supplementation in patients with heart failure has not been established, and the issue is comparatively more complex. Indeed, there are conflicting reports on the efficacy of BCAA supplementation. The evidence for including BCAA supplementation in treating patients with heart failure was reviewed, and the complexity of the issue was discussed.
Core Tip: The pros and cons of branched-chain amino acid (BCAA) supplementation can vary depending on the patient and their specific conditions. Particularly, BCAA supplementation for patients with cardiac dysfunction, who could easily be presumed to have metabolic dysfunction, should be carefully considered.
